Valsartan in chronic heart failure

Annals of Pharmacotherapy

Volumn 39, Issue 3, 2005, Pages 460-469

  Ripley, Toni L ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

Angiotensin receptor blocker; Heart failure; Valsartan

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; POTASSIUM; VALSARTAN;

ANGIONEUROTIC EDEMA; AREA UNDER THE CURVE; COUGHING; CREATININE BLOOD LEVEL; DIZZINESS; DOSE RESPONSE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULARY; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG USE; HEART FAILURE; HUMAN; HYPERKALEMIA; HYPOTENSION; KIDNEY DISEASE; PATIENT COUNSELING; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RACE; REVIEW;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; DRUG THERAPY, COMBINATION; FEMALE; FORMULARIES, HOSPITAL; HEART FAILURE, CONGESTIVE; HUMANS; KIDNEY FAILURE; LIVER DISEASES; MALE; PATIENT EDUCATION; PREGNANCY; RANDOMIZED CONTROLLED TRIALS; TETRAZOLES; VALINE;

EID: 13944258929     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E327     Document Type: Review

References (50)

1. American Heart Association. Heart disease and stroke statistics-2004 update. Dallas: American Heart Association, 2003.
2. Rich M. Epidemiology, pathophysiology, and etiology of congestive heart failure in older adults. J Am Geriatr Soc 1997;45:968-74.
3. Francis GS, Gassler JP, Sonnenblick EH. Pathophysiology and diagnosis of heart failure. In: Fuster V, Alexander RW, O'Rourke RA, Roberts R, King SB, Wellens HJJ, eds. Hurst's: the heart. 10th ed. New York: McGraw-Hill, 2001:655-85.
4. Jessup M, Brozena S. Heart failure. N Engl J Med 2003;348:2007-18.
5. The Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987;316:1429-35.
6. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91.
7. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
8. Jorde UP, Ennezat PV, Lisker J, Suryadevara V, Infeld J, Cukon S, et al. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation 2000;101:844-6.
9. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res 1990;66:883-90.
10. 2 receptor gene polymorphism is associated with angiotensin- converting enzyme inhibitor-related cough. Hypertension 2000;36:127-31.
11. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. for the US Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
12. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, et al. for the MOCHA investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996;94:2807-16.
13. Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, et al. for the PRECISE Study Group. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: the PRECISE Trial. Circulation 1996; 94:2793-9.
14. Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996;94:2800-6.
15. Cohn JN, Fowler MB, Bristow MR, Colucci WS, Gilbert EM, Kinhal V, et al. Safety and efficacy of carvedilol in severe heart failure. J Card Fail 1997;3:173-9.
16. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet 1999;353:2001-7.
17. 2 receptor subtype: an uprising frontier in cardiovascular disease. J Hypertens 2003;21:1429-43.
18. Wharton J, Morgan K, Rutherford RAD, Catravas JD, Chester A, Whitehead BF, et al. Differential distribution of angiotensin AT2 receptors in the normal and failing heart. J Pharmacol Exp Ther 1998;284:323-36.
19. Lévy BI. Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system. Circulation 2004;109:8-13.
20. Markham A, Goa KL. Valsartan: a review of its pharmacology and therapeutic use in essential hypertension. Drugs 1997;54:299-311.
21. Package insert. Diovan (valsartan). East Hanover, NJ: Novartis Pharmaceuticals, August 2002.
22. Müller P, Flesch G, de Gaspara M, Gasparini M, Howald H. Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects. Eur J Clin Pharmacol 1997;52:441-9.
23. Prasad PP, Yeh CM, Gurrieri P, Glazer R, McLeod J. Pharmacokinetics of multiple doses of valsartan in patients with heart failure. J Cardiovasc Pharmacol 2002;40:801-7.
24. Brookman LJ, Rolan PE, Benjamin IS, Palmer KR, Wyld PJ, Lloyd P, et al. Pharmacokinetics of valsartan in patients with liver disease. Clin Pharmacol Ther 1997;62:272-8.
25. Mazayev VP, Fomina IG, Kazakov EN, Sulimov VA, Zvereva TV, Lyusov VA, et al. Valsartan in heart failure patients previously untreated with an ACE inhibitor. Int J Cardiol 1998;65:239-46.
26. Baruch L, Anand I, Cohen IS, Ziesche S, Judd D, Cohn JN. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Circulation 1999;99:2658-64.
27. Cohn JN, Tognoni G, for the Valsartan Heart Failure Study Group. A randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.
28. Maggioni AP, Anand I, Gottlieb SO, Latini R, Tognoni G, Cohn JN. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2002;40:1414-21.
29. Carson P, Tognoni G, Cohn JN. Effect of valsartan on hospitalization: results from Val-HeFT. J Card Fail 2003;9:164-71.
30. Wong M, Staszewsky L, Latini R, Barlera S, Volpe A, Chiang YT, et al. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT Echocardiographic Study. J Am Coll Cardiol 2002;40:970-5.
31. McMurray JJV, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767-71.
32. Pfeffer MA, McMurray JJV, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-906.
33. Latini R, Masson S, Anand I, Judd D, Maggioni AP, Chiang YT, et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan in Heart Failure Trial. Circulation 2002;106:2454-8.
34. Benz J, Oshrain C, Henry D, Avery C, Chiang YT, Gatlin M. Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide. J Clin Pharmacol 1997;37:101-7.
35. Granger CB, McMurray JJV, Yusuf S, Held P, Michelson EL, Olofsson B, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362:772-6.
36. Exner DV, Dries DL, Domanski ML, Cohn JN. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 2001;344:1351-7.
37. Dries DL, Exner DV, Gersh BJ, Cooper HA, Carson PE, Domanski MJ. Racial differences in the outcome of left ventricular dysfunction. N Engl J Med 1999;340:609-16.
38. Weir MR, Gray JM, Paster R, Saunders E. Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients. The Trandolapril Multicenter Study Group. Hypertension 1995;26:124-30.
39. Heart Failure Society of America (HFSA) Practice Guidelines. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction-pharmacological approaches. J Card Fail 1999;5:357-82.
40. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). 2001. www.acc.org/clinical/guidelines/ failure/hf_index.htm (accessed 2004 Oct 20).
41. Schaifer C. Angiotensin II-receptor-antagonists: further evidence of fetotoxicity but not teratogenicity. Birth Defects Res A Clin Mol Teratol 2003;67:591-4.
42. McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. Circulation 1999;100: 1056-64.
43. Granger CB, Ertl G, Kuch J, Maggioni AP, McMurray J, Rouleau JL, et al. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. Am Heart J 2000;139:609-17.
44. Yusuf S, Pfeffer MA, Swedberg K, Granger DB, Held P, McMurray JJV, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet 2003;362:777-81.
45. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, Michelson EL, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall Programme. Lancet 2003;362:759-66.
46. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747-52.
47. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-The Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-7.
48. Dickstein K, Kfekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002;360:752-60.
49. Dunselman PHJM. Effects of the replacement of the angiotensin-converting enzyme inhibitor enalapril by the angiotensin II receptor blocker telmisartan in patients with congestive heart failure: the REPLACE investigators. Int J Cardiol 2001;77:131-8.
50. Bart BA, Gattis WA, Diem SJ, O'Connor CM. Reasons for underuse of angiotensin-converting enzyme inhibitors in patients with heart failure and left ventricular dysfunction. Am J Cardiol 1997;79:1118-20.